Phobic Disorders Clinical Trial
Official title:
Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants
Verified date | September 2018 |
Source | VU University of Amsterdam |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Procedurally Virtual reality exposure therapy (VRET) is quite similar to models of extinction of conditioned fears. Recent advances in animal research have identified pharmacological agents that appear to both accelerate and consolidate extinction learning. One of these cognitive enhancers is Yohimbine. An interesting finding in animal literature is that the administration of Yohimbine during extinction trials accelerates fear reduction and may convert ineffective exposures in to successful ones. It is thought that the mechanism of enhanced emotional memory is through elevated norepinephrine in the prefrontal cortex. Therefore, we propose to extend these studies by combining VRET with Yohimbine. In this pilot study with a between groups design 20 participants with a fear of flying will be treated with VRET plus Yohimbine or VRET plus placebo. This between groups design was chosen to further characterize the differential within and between trial extinction. Outcome will be measured by self-report, behavioral, and psychophysiological assessments at pre- and post-treatment. In addition, we will examine extinction parameters during exposures.
Status | Completed |
Enrollment | 67 |
Est. completion date | July 2010 |
Est. primary completion date | June 2009 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - DSM-IV diagnosis of specific phobia (fear of flying). - Between the ages of 18-65 - Sufficient fluency in Dutch to complete treatment and research protocol Exclusion Criteria: - Presence of medical condition, assessed by self-report questionnaires at the intake (i.e., pregnancy, seizure disorder, respiratory disorder, cardiovascular disease, pacemaker, hypertension). - Resting blood pressure higher than 140 (systolic) or 105 (diastolic) - Unstable psychotropic medication. - Current use of tranquilizers (Benzodiazepines) - Psychosis - Depression with suicidal ideation - Dementia or other severe cognitive impairment - Substance dependence - Bipolar disorder - Borderline personality disorder - Anti-social personality disorder - Current use of beta-blockers |
Country | Name | City | State |
---|---|---|---|
Netherlands | University of Amsterdam | Amsterdam |
Lead Sponsor | Collaborator |
---|---|
VU University of Amsterdam |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Flight Anxiety Situations Questionnaire (self-report); Flight Anxiety Modality Questionnaire (self-report) | Assessed at pre- and post-treatment and 9-12 months follow-up | ||
Secondary | Severity of Anxiety Symptoms (Beck Anxiety Inventory) Anxiety Sensitivity (Anxiety Sensitivity Inventory) | Assessed at pre- and post-treatment and 9-12 months follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01963806 -
ACT-smart: Smartphone-supplemented iCBT for Social Phobia and/or Panic Disorder
|
N/A | |
Completed |
NCT00121069 -
Study of Escitalopram in the Treatment of Specific Phobia
|
Phase 2/Phase 3 | |
Recruiting |
NCT03653923 -
Neurophysiological Correlates of Exposition Therapy in Spider Phobia
|
N/A | |
Completed |
NCT00184106 -
RCT of Cognitive Therapy, Paroxetine, Combined CT and Paroxetine and Placebo
|
Phase 4 | |
Completed |
NCT00051220 -
Treatment for Specific Phobias in Children
|
Phase 1/Phase 2 | |
Completed |
NCT02387047 -
Validity of a Self-administered Questionnaire to Screen Phobia of Falling in the Elderly
|
N/A | |
Completed |
NCT02310152 -
Explanatory Clinical Trial of a Novel Parent Intervention for Childhood Anxiety (SPACE)
|
N/A | |
Completed |
NCT00000370 -
Treatment of Social Phobia
|
N/A | |
Completed |
NCT03012035 -
The Role of Treatment Expectation in Exposure Training With Spider Fearful Participants
|
N/A | |
Completed |
NCT02007694 -
Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03188575 -
Effectiveness & Cost-effectiveness of Internet-delivered Interventions for Depression and Anxiety Disorders in IAPT
|
N/A | |
Completed |
NCT02432703 -
A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder
|
Phase 2 | |
Terminated |
NCT01574014 -
Glucocorticoid Treatment for Social Phobia
|
Phase 2 | |
Not yet recruiting |
NCT02336802 -
Threat-Avoidance Learning in Anxiety Patients
|
N/A | |
Completed |
NCT01361074 -
In Vivo Versus Augmented Reality Exposure for Small Animal Phobia
|
N/A | |
Completed |
NCT00104195 -
A Research Study of How Teens With and Without an Anxiety Disorder Make Decisions
|
Phase 1 | |
Completed |
NCT00035412 -
St. John's Wort Versus Placebo in Social Phobia
|
Phase 2 | |
Completed |
NCT00128401 -
Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia
|
Phase 2 | |
Recruiting |
NCT02020824 -
Virtual Reality and Concept of Control in the Treatment of Acrophobia
|
N/A | |
Terminated |
NCT01623583 -
Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias
|
Phase 4 |